Regeneron Pharmaceuticals stock is trading -12.64% below its average target price of $1176.79 after dropping -5.9% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $805.0 to $1300.0 per share.
The stock has an average amount of shares sold short at 2.0%, and a short ratio of 4.46. The company's insiders own 1.53% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 89.8% of Regeneron Pharmaceuticals's shares being owned by this investor type.
Institutions Invested in Regeneron Pharmaceuticals
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | FMR, LLC | 10% | 10,649,474 | $10,948,617,360 |
| 2024-06-30 | Vanguard Group Inc | 8% | 8,993,970 | $9,246,610,309 |
| 2024-06-30 | Blackrock Inc. | 8% | 8,446,366 | $8,683,624,132 |
| 2024-06-30 | JP Morgan Chase & Company | 8% | 8,277,315 | $8,509,824,495 |
| 2024-06-30 | State Street Corporation | 4% | 4,841,127 | $4,977,114,091 |
| 2024-06-30 | Capital World Investors | 4% | 4,638,667 | $4,768,966,997 |
| 2024-06-30 | Capital International Investors | 3% | 3,134,122 | $3,222,159,379 |
| 2024-06-30 | Geode Capital Management, LLC | 2% | 2,415,350 | $2,483,197,098 |
| 2024-06-30 | Dodge & Cox Inc | 2% | 2,315,686 | $2,380,733,540 |
| 2024-06-30 | Franklin Resources, Inc. | 2% | 1,923,102 | $1,977,121,869 |
Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on Regeneron Pharmaceuticals.
